ILF2 and hepatocellular carcinoma: Studies have shown high ILF2 expression in esophageal squamous cell carcinoma (ESCC) (16), hepatocellular carcinoma (HCC) (14), non-small-cell lung cancer (NSCLC) (29), pancreatic ductal adenocarcinoma (PDAC) (12), gastric cancer (30), breast cancer (9), and gliomas (31).